New research published in Scientific Reports reveals that the corticosteroid prednisone suppresses key bone and cartilage biomarkers in young boys with Duchenne muscular dystrophy, while an alternative drug, vamorolone, does not. According to an international research team, the findings offer fresh biological insight into why traditional steroids drive childhood growth failure, whereas newer bone-sparing alternatives may protect skeletal health during chronic treatment.
Biomarker Differences Between Prednisone and Vamorolone
Corticosteroids remain a primary treatment for managing Duchenne muscular dystrophy, but their tendency to cause osteopenia and growth deceleration presents significant clinical challenges. The study involved the analysis of serial blood serum specimens gathered from a trial of vamorolone in boys ranging from 4 to under 7 years old that used both placebos and prednisone in a double-blind design. During the initial 24-week phase, participants received a placebo, prednisone at 0.75 mg/kg/day, or vamorolone at 6 mg/kg/day. In the subsequent 24-week phase, the placebo and prednisone groups crossed over to vamorolone treatment. Standard clinical laboratory tests showed that alkaline phosphatase, osteocalcin, procollagen type I N-terminal propeptide, and collagen type I C-terminal telopeptide declined significantly under prednisone. By contrast, these markers remained unchanged in participants receiving vamorolone or a placebo, according to the data.
Did You Know?
When participants transitioned from prednisone to vamorolone during the trial crossover, suppressed biomarkers returned toward their pre-treatment baseline levels, suggesting a reversible drug effect rather than disease progression.
Proteomic Screening Identifies Ten Prednisone-Specific Proteins
Beyond standard bone turnover tests, broader proteomic screening identified 10 serum proteins reduced specifically by prednisone treatment. According to the researchers, these proteins correspond to genes implicated in genetic disorders of bone and cartilage, including collagens such as COL2A1, chondrocalcin, COL6A1, COL9A1, COL10A1, and COL11A2. Other affected molecules included the aggrecan core protein, biglycan, osteopetrosis-associated transmembrane protein 1, and noggin. The reversibility of these biomarker alterations following participant crossover was highlighted by Utkarsh Dang, a professor in the Department of Health Sciences at Carleton University who also served as the lead statistician for the research.
Growth Plate Activity and Clinical Monitoring
The identified biomarkers point directly to prednisone-driven apoptosis of hypertrophic chondrocytes and osteoblasts, which are cells responsible for bone formation and lengthening in children. According to Eric P. Hoffman, senior author of the study and associate dean for research at Binghamton University, both prednisone and vamorolone improved motor outcomes during the trial, but only prednisone produced this adverse biomarker pattern. Change in height z-scores correlated most strongly with changes in alkaline phosphatase among corticosteroid-treated boys. Clinicians may eventually use these biomarkers, particularly alkaline phosphatase and COL10A1, to monitor growth plate health and guide drug selection, pending further validation.
Frequently Asked Questions
- What is Duchenne muscular dystrophy? Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness, frequently managed with chronic corticosteroid therapy.
- How do prednisone and vamorolone differ in their effects on bone? While both drugs improve motor outcomes, prednisone suppresses bone turnover markers and growth-related proteins, whereas vamorolone preserves these biomarkers without causing the same deceleration in linear growth.
- What biomarkers were analyzed in the study? Researchers tracked standard markers like alkaline phosphatase and osteocalcin, alongside ten proteomic serum proteins linked to bone and cartilage development.
Stay Informed on Pediatric Research
Subscribe to our newsletter to receive the latest updates on neuromuscular disease research, clinical trials, and breakthrough biomedical findings.
Related reading